title: Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.
abstract: OBJECTIVE
  To examine the relationship between levels of the T-cell regulatory cytokine interleukin-7 (IL-7) and CD4 cell counts during immune reconstitution and to assess its prognostic value in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.
  
  
  METHODS
  Thirty-six HIV-1-infected adults who completed 48 weeks of follow-up visits were included in this prospective study. Patients having failed two or more antiretroviral therapy regimens were treated with lopinavir/ritonavir-based therapy. An enzyme-linked immunosorbent assay was used to determine IL-7 plasma levels, flow cytometry was used to analyse cell surface antigens, and polymerase chain reaction was used to quantify plasma HIV-1.
  
  
  RESULTS
  Pretreatment IL-7 levels were elevated in all patients (mean 11.0 pg/mL) and were negatively correlated with CD4 cell counts and age (r=-0.59, P<0.001 and r=-0.57, P<0.001, respectively). During the course of treatment, IL-7 levels decreased by 34% while CD4 cell numbers progressively increased by 88%. Multivariate regression analysis showed that only pretreatment IL-7 levels predicted viral load at 48 weeks when controlling for baseline CD4 cell counts, viral load and patient demographics.
  
  
  CONCLUSIONS
  These findings are consistent with regulation of T-cell recovery by IL-7, and suggest that IL-7 measurements might be used to predict virological response.
authors.affiliation: Immunodeficiency Service Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
authors.forename: M R
authors.initials: MR
authors.lastname: Boulassel
authors.forename: G H R
authors.initials: GH
authors.lastname: Smith
authors.forename: N
authors.initials: N
authors.lastname: Gilmore
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: T
authors.initials: T
authors.lastname: Murphy
authors.forename: J
authors.initials: J
authors.lastname: MacLeod
authors.forename: R
authors.initials: R
authors.lastname: LeBlanc
authors.forename: J
authors.initials: J
authors.lastname: Allan
authors.forename: P
authors.initials: P
authors.lastname: René
authors.forename: R G
authors.initials: RG
authors.lastname: Lalonde
authors.forename: J P
authors.initials: JP
authors.lastname: Routy
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D015851:Interleukin-7 / Q000097:blood*; D061466:Lopinavir; D018655:Lymphocyte Count; D008297:Male; D011446:Prospective Studies; D011744:Pyrimidinones / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000378:metabolism; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015851:Interleukin-7; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir